Drug Discovery Articles

Review: Transient receptor potential channels: targeting pain at the source

Pain results from the complex processing of neural signals at different levels of the central nervous system, with each signal potentially offering multiple opportunities for pharmacological intervention. A logical strategy for developing novel analgesics is to target the beginning of the pain pathway, and aim

Nature Reviews Drug Discovery, vol. 8 #1, pp55-68

Review: Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders

Despite G-protein-coupled receptors (GPCRs) being among the most fruitful targets for marketed drugs, intense discovery efforts for several GPCR subtypes have failed to deliver selective drug candidates. Historically, drug discovery programmes for GPCR ligands have been dominated by efforts to develop agonists and antagonists that

Nature Reviews Drug Discovery, vol. 8 #1, pp41-54

Perspective: Is NF-κB a good target for cancer therapy? Hopes and pitfalls

Nuclear factor κB (NF-κB) transcription factors have a key role in many physiological processes such as innate and adaptive immune responses, cell proliferation, cell death, and inflammation. It has become clear that aberrant regulation of NF-κB and the signalling pathways that control its activity are

Nature Reviews Drug Discovery, vol. 8 #1, pp33-40

Perspective: Chemokine receptor antagonists: overcoming developmental hurdles

Chemokine receptors have a key role in the pathogenesis of autoimmune diseases, inflammation and viral infection. However, with the exception of selective CCR5 antagonists for HIV, the promise of obtaining new therapeutics related to chemokine receptors has not yet been realized. This article highlights some

Nature Reviews Drug Discovery, vol. 8 #1, pp23-33

Review: Drug development from marine natural products

Drug discovery from marine natural products has enjoyed a renaissance in the past few years. Ziconotide (Prialt; Elan Pharmaceuticals), a peptide originally discovered in a tropical cone snail, was the first marine-derived compound to be approved in the United States in December 2004 for the

Nature Reviews Drug Discovery, vol. 8 #1, pp69-85



Extra navigation

ADVERTISEMENT